Delaware | 000-06920 | 94-1655526 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
3050 Bowers Avenue | ||
P.O. Box 58039 | ||
Santa Clara, CA | 95052-8039 | |
(Address of principal executive | (Zip Code) | |
offices) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition | ||||||||
Item 9.01 Financial Statements and Exhibits | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EX-99.1 |
Exhibit No. | Description | |
99.1
|
Press Release issued by Applied Materials, Inc. dated May 12, 2009. |
Applied Materials, Inc. (Registrant) |
||||
Date: May 12, 2009 | By: | /s/ Joseph J. Sweeney | ||
Joseph J. Sweeney | ||||
Senior Vice President, General Counsel and Corporate Secretary |
Exhibit No. | Description | |
99.1
|
Press Release issued by Applied Materials, Inc. dated May 12, 2009. |
David Miller (editorial/media) 408.563.9582 Michael Sullivan (financial community) 408.986.7977 |
Q2 FY 09 | Q1 FY 09 | Q2 FY 08 | ||||
Net sales | $1.02 billion | $1.33 billion | $2.15 billion | |||
Net income (loss) | ($255 million) | ($133 million) | $303 million | |||
Earnings (loss) per share | ($0.19) | ($0.10) | $0.22 |
Q2 FY 09 | Q1 FY 09 | Q2 FY 08 | ||||
Non-GAAP net income (loss) | ($136 million) | ($3 million) | $362 million | |||
Non-GAAP earnings (loss) per share | ($0.10) | $0.00 | $0.26 |
Q2 FY 09 | Q1 FY 09 | Q2 FY 08 | ||||||||||||||||||||||||||||||||||
New | Net | Operating Income |
New | Net | Operating Income |
New | Net | Operating Income |
||||||||||||||||||||||||||||
(In millions) | Orders | Sales | (Loss) | Orders | Sales | (Loss) | Orders | Sales | (Loss) | |||||||||||||||||||||||||||
Silicon |
$ | 259 | $ | 260 | ($96 | ) | $ | 246 | $ | 546 | $ | 34 | $ | 1,061 | $ | 1,268 | $ | 448 | ||||||||||||||||||
Applied Global
Services |
$ | 236 | $ | 319 | ($1 | ) | $ | 310 | $ | 345 | $ | 26 | $ | 602 | $ | 599 | $ | 159 | ||||||||||||||||||
Display |
$ | 13 | $ | 84 | $ | 1 | $ | 26 | $ | 149 | $ | 26 | $ | 493 | $ | 198 | $ | 59 | ||||||||||||||||||
Energy and
Environmental
Solutions |
$ | 141 | $ | 357 | ($93 | ) | $ | 321 | $ | 293 | ($65 | ) | $ | 257 | $ | 85 | ($71 | ) |
Three Months Ended | Six Months Ended | |||||||||||||||
April 26, | April 27, | April 26, | April 27, | |||||||||||||
(In thousands, except per share amounts) | 2009 | 2008 | 2009 | 2008 | ||||||||||||
Net sales |
$ | 1,020,077 | $ | 2,149,998 | $ | 2,353,473 | $ | 4,237,395 | ||||||||
Cost of products sold |
864,558 | 1,183,170 | 1,806,378 | 2,335,586 | ||||||||||||
Gross margin |
155,519 | 966,828 | 547,095 | 1,901,809 | ||||||||||||
Operating expenses: |
||||||||||||||||
Research, development and engineering |
236,335 | 287,122 | 465,875 | 560,341 | ||||||||||||
General and administrative |
101,080 | 122,035 | 242,321 | 238,011 | ||||||||||||
Marketing and selling |
84,678 | 119,410 | 168,793 | 243,327 | ||||||||||||
Restructuring and asset impairments |
26,709 | 510 | 159,481 | 49,496 | ||||||||||||
Income (loss) from operations |
(293,283 | ) | 437,751 | (489,375 | ) | 810,634 | ||||||||||
Pre-tax loss of equity method investment |
19,175 | 9,766 | 34,983 | 19,352 | ||||||||||||
Impairment of equity method investment
and strategic investments |
77,081 | | 77,081 | | ||||||||||||
Interest expense |
5,058 | 6,256 | 11,052 | 10,801 | ||||||||||||
Interest income |
11,789 | 32,414 | 27,024 | 62,984 | ||||||||||||
Income (loss) before income taxes |
(382,808 | ) | 454,143 | (585,467 | ) | 843,465 | ||||||||||
Provision (benefit) for income taxes |
(127,418 | ) | 151,636 | (197,143 | ) | 278,582 | ||||||||||
Net income (loss) |
$ | (255,390 | ) | $ | 302,507 | $ | (388,324 | ) | $ | 564,883 | ||||||
Earnings (loss) per share: |
||||||||||||||||
Basic |
$ | (0.19 | ) | $ | 0.22 | $ | (0.29 | ) | $ | 0.41 | ||||||
Diluted |
$ | (0.19 | ) | $ | 0.22 | $ | (0.29 | ) | $ | 0.41 | ||||||
Weighted average number of shares: |
||||||||||||||||
Basic |
1,331,729 | 1,356,705 | 1,330,476 | 1,363,975 | ||||||||||||
Diluted |
1,331,729 | 1,373,314 | 1,330,476 | 1,379,071 | ||||||||||||
April 26, | October 26, | |||||||
(In thousands) | 2009 | 2008 | ||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 1,466,976 | $ | 1,411,624 | ||||
Short-term investments |
597,389 | 689,044 | ||||||
Accounts receivable, net |
914,392 | 1,691,027 | ||||||
Inventories |
1,901,024 | 1,987,017 | ||||||
Deferred income taxes, net |
390,025 | 388,807 | ||||||
Income taxes receivable |
300,401 | 125,605 | ||||||
Other current assets |
344,599 | 371,033 | ||||||
Total current assets |
5,914,806 | 6,664,157 | ||||||
Long-term investments |
1,000,705 | 1,367,056 | ||||||
Property, plant and equipment |
2,864,396 | 2,831,952 | ||||||
Less: accumulated depreciation and amortization |
(1,774,273 | ) | (1,737,752 | ) | ||||
Net property, plant and equipment |
1,090,123 | 1,094,200 | ||||||
Goodwill, net |
1,171,740 | 1,174,673 | ||||||
Purchased technology and other intangible assets, net |
347,117 | 388,429 | ||||||
Equity method investment |
| 79,533 | ||||||
Deferred income taxes and other assets |
224,608 | 238,270 | ||||||
Total assets |
$ | 9,749,099 | $ | 11,006,318 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
Current liabilities: |
||||||||
Current portion of long-term debt |
$ | 1,156 | $ | 1,068 | ||||
Accounts payable and accrued expenses |
1,047,915 | 1,545,355 | ||||||
Customer deposits and deferred revenue |
962,975 | 1,225,735 | ||||||
Income taxes payable |
120,787 | 173,394 | ||||||
Total current liabilities |
2,132,833 | 2,945,552 | ||||||
Long-term debt |
201,165 | 201,576 | ||||||
Other liabilities |
319,202 | 310,232 | ||||||
Total liabilities |
2,653,200 | 3,457,360 | ||||||
Stockholders equity: |
||||||||
Common stock |
13,330 | 13,308 | ||||||
Additional paid-in capital |
5,155,301 | 5,095,894 | ||||||
Retained earnings |
11,031,711 | 11,601,288 | ||||||
Treasury stock |
(9,100,915 | ) | (9,134,962 | ) | ||||
Accumulated other comprehensive loss |
(3,528 | ) | (26,570 | ) | ||||
Total stockholders equity |
7,095,899 | 7,548,958 | ||||||
Total liabilities and stockholders equity |
$ | 9,749,099 | $ | 11,006,318 | ||||
Six Months Ended | ||||||||
April 26, | April 27, | |||||||
(In thousands) | 2009 | 2008 | ||||||
Cash flows from operating activities: |
||||||||
Net income (loss) |
$ | (388,324 | ) | $ | 564,883 | |||
Adjustments required to reconcile net income (loss) to cash provided
by (used in) operating activities: |
||||||||
Depreciation and amortization |
146,108 | 154,321 | ||||||
Loss on fixed asset retirements |
7,002 | 21,527 | ||||||
Provision for bad debts |
62,539 | | ||||||
Restructuring and asset impairments |
159,481 | 49,496 | ||||||
Deferred income taxes |
35,927 | (38,538 | ) | |||||
Excess tax benefits from equity-based compensation plans |
| (5,406 | ) | |||||
Net recognized loss (gain) on investments |
10,915 | (3,560 | ) | |||||
Pretax loss of equity-method investment |
34,983 | 19,352 | ||||||
Impairment of equity-method investment and strategic investments |
77,081 | | ||||||
Equity-based compensation |
72,780 | 89,044 | ||||||
Changes in operating assets and liabilities, net of amounts acquired: |
||||||||
Accounts receivable |
714,096 | 385,830 | ||||||
Inventories |
85,993 | (277,478 | ) | |||||
Other current assets |
13,411 | 116,352 | ||||||
Other assets |
(1,144 | ) | (4,875 | ) | ||||
Accounts payable and accrued expenses |
(649,976 | ) | (107,155 | ) | ||||
Customer deposits and deferred revenue |
(262,760 | ) | 302,195 | |||||
Income taxes |
(246,739 | ) | (11,803 | ) | ||||
Other liabilities |
27,710 | 9,548 | ||||||
Cash provided by (used in) operating activities |
(100,917 | ) | 1,263,733 | |||||
Cash flows from investing activities: |
||||||||
Capital expenditures |
(128,099 | ) | (137,699 | ) | ||||
Cash paid for acquisition, net of cash acquired |
| (235,324 | ) | |||||
Proceeds from sales and maturities of investments |
925,485 | 3,131,994 | ||||||
Purchases of investments |
(486,527 | ) | (3,376,917 | ) | ||||
Cash provided by (used in) investing activities |
310,859 | (617,946 | ) | |||||
Cash flows from financing activities: |
||||||||
Debt repayments |
(323 | ) | (12 | ) | ||||
Proceeds from common stock issuances |
27,633 | 308,463 | ||||||
Common stock repurchases |
(22,906 | ) | (899,984 | ) | ||||
Excess tax benefits from equity-based compensation plans |
| 5,406 | ||||||
Payment of dividends to stockholders |
(159,736 | ) | (164,274 | ) | ||||
Cash used in financing activities |
(155,332 | ) | (750,401 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents |
742 | 151 | ||||||
Increase (decrease) in cash and cash equivalents |
55,352 | (104,463 | ) | |||||
Cash and cash equivalents beginning of period |
1,411,624 | 1,202,722 | ||||||
Cash and cash equivalents end of period |
$ | 1,466,976 | $ | 1,098,259 | ||||
Supplemental cash flow information: |
||||||||
Cash payments for income taxes |
$ | 83,128 | $ | 167,185 | ||||
Cash payments for interest |
$ | 7,211 | $ | 7,229 |
Three Months Ended | Six Months Ended | |||||||||||||||||||
April 26, | April 27, | January 25, | April 26, | April 27, | ||||||||||||||||
(In thousands, except per share amounts) | 2009 | 2008 | 2009 | 2009 | 2008 | |||||||||||||||
Non-GAAP Net Income (Loss) |
||||||||||||||||||||
Reported net income (loss) (GAAP basis) |
$ | (255,390 | ) | $ | 302,507 | $ | (132,934 | ) | $ | (388,324 | ) | $ | 564,883 | |||||||
Equity-based compensation expense |
39,172 | 50,322 | 33,608 | 72,780 | 89,044 | |||||||||||||||
Certain items associated with acquisitions 1 |
24,824 | 31,144 | 26,025 | 50,849 | 62,182 | |||||||||||||||
Restructuring and asset impairments 2,3,4 |
26,709 | 510 | 132,772 | 159,481 | 49,496 | |||||||||||||||
Costs associated with ceasing development
of beamline implant products 5 |
| 259 | | | 1,280 | |||||||||||||||
Impairment of equity method investment and
strategic investments |
77,081 | | | 77,081 | | |||||||||||||||
Income tax
effect of non-GAAP adjustments and resolution of audits of prior
years income tax filings |
(48,040 | ) | (23,142 | ) | (62,939 | ) | (110,979 | ) | (60,468 | ) | ||||||||||
Non-GAAP net income (loss) |
$ | (135,644 | ) | $ | 361,600 | $ | (3,468 | ) | $ | (139,112 | ) | $ | 706,417 | |||||||
Non-GAAP Net Income (Loss) Per Diluted Share |
||||||||||||||||||||
Reported net income (loss) per diluted share
(GAAP basis) |
$ | (0.19 | ) | $ | 0.22 | $ | (0.10 | ) | $ | (0.29 | ) | $ | 0.41 | |||||||
Equity-based compensation expense |
0.02 | 0.03 | 0.02 | 0.04 | 0.05 | |||||||||||||||
Certain items associated with acquisitions |
0.01 | 0.02 | 0.01 | 0.03 | 0.03 | |||||||||||||||
Restructuring and asset impairments |
0.01 | | 0.06 | 0.08 | 0.02 | |||||||||||||||
Costs associated with ceasing development
of beamline implant products |
| | | | | |||||||||||||||
Impairment of equity method investment and
strategic investments |
0.05 | | | 0.05 | | |||||||||||||||
Resolution of audits of prior years income tax filings |
(0.01 | ) | | | (0.01 | ) | | |||||||||||||
Non-GAAP net income (loss) per diluted share |
$ | (0.10 | ) | $ | 0.26 | $ | 0.00 | $ | (0.10 | ) | $ | 0.51 | ||||||||
Shares used in diluted shares calculation |
1,331,729 | 1,373,314 | 1,329,223 | 1,330,476 | 1,379,071 | |||||||||||||||
1 | Incremental charges attributable to acquisitions consisting of inventory fair value adjustments on products sold and amortization of purchased intangible assets. | |
2 | Results for the three months ended April 26, 2009 included asset impairment charges of $15 million related to wafer cleaning equipment and restructuring charges of $12 million primarily associated with a restructuring program announced on November 12, 2008. Results for the six months ended April 26, 2009 included asset impairment charges of $15 million related to wafer cleaning equipment and restructuring charges of $145 million associated with a restructuring program announced on November 12, 2008. | |
3 | Results for the six months ended April 27, 2008 included restructuring charges of $38 million associated with a global cost reduction plan. | |
4 | Results for the three and six months ended April 27, 2008 included restructuring and asset impairment charges of $510,000 and $12 million, respectively, associated with ceasing development of beamline implant products. | |
5 | Results for the three and six months ended April 27, 2008 included other operating charges of $259,000 and $1 million associated with ceasing development of beamline implant products. |